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BACKGROUND
Chronic kidney disease (CKD) is a complex 
condition which impacts on an individual’s 
quality of life (QoL) and ability to perform 
everyday activities. Fatigue is also a common 
symptom experienced by people with CKD.
Little, however, is known about the influence of 
anaemia and whether fatigue contributes to QoL
and activity levels. This study builds on previous 
research 1-3
RESULTS
 Of the 29 renal patients, 5 died, 2 withdrew & 1 lost to follow-up.
 Ages 31 to 84 years (mean = 64).
 Table 1 reveals descriptive scores for each time point.
 QoL was low & did not change from baseline to 12 months after
commencing an ESA (Table 2).
 Levels of fatigue significantly improved over time (λ=.492, F(3,11)=3.78, p<.05).
 Table 3 shows that the highest levels of fatigue occur when the ESA is
t t d (b li ) d l t 6 th l t.
RESEARCH QUESTION
Does QoL, activity and fatigue levels of people 
with anaemia secondary to CKD change over a 
12 month period following the introduction of 
erythropoietin stimulating agent (ESA)?
METHODS
Design: Longitudinal repeated measure 
Sample: 29 people with CKD
Data collected at baseline, 3, 6 & 12 months: 
 Demographic - age, gender & marital status
 Renal History - cause of renal failure, 
haematology and biochemistry results and 
anaemia therapy.
 Instruments -
i) Quality of Life (SF-36)
ii) Human Activity Profile (HAP)
iii) Fatigue Severity Scale (FSS)
s ar e ase ne an was owes mon s a er.
 Activity level (HAP) did not improve over time (λ = .669, F(3,13)=2.14, ns).
Table 2 Change in Quality of Life 
Subscales λ
Wilks Lambda
F p N η2
Partial Eta Squared
Physical functioning .786 1.17 ns* 16 .214
Role physical .892 .725 ns 21 .108
Bodily pain .951 .292 ns 20 .049
General health .628 1.97 ns 13 .372
Vitality .88 .499 ns 14 .12
Social functioning .932 .338 ns 17 .068
Table 3 Level of Fatigue 
Mean SD
Baseline 49 0 13 23
Table 1 Quality of Life, Activity & Fatigue Scores Over Time
Baseline
Mean (SD)
3 months
Mean (SD)
6 months
Mean (SD)
12 months
Mean (SD)
SF36 (mental health 46.92 (7.23) 46.73 (4.99) 46.71 (3.1) 48.44 (3.65)
SF36 (physical health) 45.25 (6.6) 46.86 (5.73) 46.76 (4.96) 48.43 (4.6)
HAP  (activity level) 43.40 (17.76) 47.95 (20.07) 47.61 (23.68) 48.22 (23.23)
FSS   (fatigue level) 47.69 (13.18) 47.61 (12.87) 38.70 (17.18) 42.35 (13.19)
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IMPLICATIONS FOR PRACTICE
 There is a need for increased assessment by nurses to identify and monitor changes in QoL, fatigue and activity levels in people
with CKD.
 Early detection of a person’s inability to engage in normal daily activities due to increasing levels of fatigue is necessary.
 Early detection would enable timely nursing interventions to optimise QoL and independent activity.
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Role emotional .842 .812 ns 16 .158
Mental health .762 1.14 ns 14 .238
Physical health .679 1.42 ns 12 .321
Total mental health .728 1.37 ns 14 .272
* p>.05
. .
3 months 46.8 13.05
6 months 39.2 18.54
12 months 42.2 13.52
